Dear Global Huntington’s Disease Community,
We are pleased to share with you an important update on the clinical development program for Sage Therapeutics, Inc.’s investigational drug, SAGE-718. We are happy to announce that the SURVEYOR Study, a Phase 2 real-world functioning study, is now open for enrollment. The SURVEYOR Study is a randomized, placebo-controlled, double-blind study designed to evaluate the cognitive performance differences between participants with Huntington’s disease (HD) and non-HD participants. The study will also evaluate the potential effects of SAGE-718 on cognition and functioning, and its safety and tolerability, in participants with pre-manifest or early manifest HD.
